KLBF – 1H25 growth tempered by weak rupiah and purchasing power

KLBF – 1H25 growth tempered by weak rupiah and purchasing power Kalbe Farma (KLBF) recorded positive results in 1H25, though its performance was tempered by the weakening rupiah and pressure on consumer purchasing power. The company's revenue grew 1.97% yoy to IDR17.1 tn, while net profit increased by 9.4% yoy. Growth was primarily driven by the pharmaceutical (+8% yoy) and distribution (+8.4% yoy) segments, while the nutritional segment remained relatively stagnant, reflecting the impact on consumer spending. To maintain long-term competitiveness, KLBF continues its expansion plans, including the construction of a new radiopharmaceutical factory and a partnership with China's Livzon Pharmaceutical Group Inc. (Source : Kontan)